Combining depot antipsychotic medications with novel antipsychotics in forensic patients: A practice in search of a principle

Psychiatric Bulletin

Volumn 27, Issue 1, 2003, Pages 14-16

  Bains, Jatinder J S ^a,c   Nielssen, Olav B ^b  

^a MANLY HOSPITAL   (Australia)

^b Offender Services and Programs Branch   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FORENSIC PSYCHIATRY; HEALTH SURVEY; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL PATIENT; PATIENT COMPLIANCE; PREVALENCE; PRISONER; PSYCHIATRIST; PSYCHOSIS; SIDE EFFECT; THERAPY RESISTANCE;

EID: 0037235476     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.27.1.14     Document Type: Article

References (15)

1. American Psychiatric Association (1997) Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154, April Suppl., 1-63.
2. Beck, N. C., Greenfield, S. R., Gotham, H., et al (1997) Risperidone in the management of violent, treatment of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. Journal of the American Academy of Psychiatry and Law, 25, 461-468.
3. Brecher M. (1996) Long term safety of risperidone (abstract P-15-1). European Neuropsychopharmacology, 6, suppl.3, 170.
4. British Medical Association & Royal Pharmaceutical Society of Great Britain (2001) British National Formulary (March issue). London & Wallingford: BMJ Books & Pharmaceutical Press.
5. Daniel, D. G. & Whitcomb, S. R. (1998) Treatment of the refractory schizophrenic patient. Journal of Clinical Psychiatry, 59, suppl. 1, 13-19, discussion 20-1.
6. Duncan, J. C. & Rogers, R. (1998) Medication compliance in patients with chronic schizophrenia; Implications for the community management of mentally disordered offenders. Journal of Forensic Psychiatry, 43, 1133-1137.
7. Frankenburg, F. R. (1999) Choices in antipsychotic therapy in schizophrenia. Harvard Research Review, 6, 241-249.
8. Lambert, T. & Singh, B. (2000) Psychotropic prescribing in community mental health clinics. International Journal of Neuropsychopharmacology, 3 (suppl.1), S123.
9. Norrie, P.D. & Hustig, H. H. (1998) A relevant indication for polypharmacy? The use of zuclopenthixol with risperidone or olanzapine in patients with treatment resistant schizophrenia. Poster 21st CINP, Glasgow, July 12-16.
10. Pantelis, C. & Barnest T. R. (1996) Drug strategies and treatment-resistant schizophrenia. Australian and New Zealand Journal of Psychiatry, 30, 20-37.
11. Swartz, M. S., Swanson, J. W., Hiday, V. A., et al (1998) Taking the wrong drugs: The role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Social Psychiatry and Psychiatric Epidemiology, 33, suppl. 1, S75-80.
12. Thompson C. (1994) The use of high dose antipsychotic medication. British Journal of Psychiatry, 164, 448-458.
13. Umbricht, D. & Kane, J. M. (1996) Understanding the relationship between extrapyrimidal side effects and tardive dyskinesia. In Serotonergic Mechanisms in Antipsychotic Treatment (eds. J. M. Kane, H. J. Moller & E. Awouters), pp. 221-251. New York: Marcel Dekker.
14. Weiden, P. J., Aquila, R., Emanuel, M., et al (1998) Long term considerations after switching antipsychotics. Journal of Clinical Psychiatry, 159, suppl. 19, 36-49.
15. Young, J. L., Zonana, H.V. & Shepler, L. (1986) Medication noncompliance in schizophrenia: Codification and update. Bulletin of the American Academy of Psychiatry and Law, 14, 105-122.